FDA Approves First-in-Class Microbiota-Based Live Biotherapeutic for C. Difficile Infection
Summary- The FDA has approved fecal microbiota, live-jslm (Rebyota; Ferring Pharmaceuticals) for the prevention of recurring Clostridioides difficile infection (CDI) among patients 18…